News

A study investigating the effects of fasting and the ketogenic diet has revealed a new vulnerability of pancreatic tumors to a cancer drug currently in clinical trials.

A recent study found that ubrogepant, a CGRP receptor antagonist, is effective in treating migraines during the prodrome phase. In a phase 3 trial, 65% of patients reported minimal limitations after treatment with ubrogepant.

Researchers identified new antivirulence and antibacterial compounds from actinobacteria found in the Arctic Ocean. These findings highlight the potential of antivirulence compounds as alternative treatments for bacterial infections.

Morphine is a powerful painkiller that belongs to the group of opioids. Researchers have now discovered the neural processes behind how morphine relieves pain, which is valuable knowledge due to the drug's serious side effects.

Research reveals that overgrowth of methane-producing archaea in the gut is linked to severe constipation. The study suggests that identifying and treating intestinal methanogen overgrowth (IMO) could lead to more effective, personalized treatments.

New research suggests that ribociclib, a drug used for breast cancer, may help slow the growth of diffuse hemispheric glioma (DHG) in children. The study revealed that ribociclib targets cancer cells disrupting neuron development.

The University of Calgary is testing probenecid, a drug for gout, to alleviate opioid withdrawal symptoms. Researchers found that probenecid reduces withdrawal pain in rodents by disrupting abnormal brain-spinal cord communication.

Researchers develop a patent-pending platform technology that mimics the dual-layer structure of viruses to deliver nucleic acid (NA)-based therapies to targeted cancer cells.

Researchers at the Weizmann Institute have found that Copaxone, originally developed for multiple sclerosis, may aid heart attack recovery. In animal studies, Copaxone improved heart function, reduced scar tissue, and protected heart muscle cells.

The combination of standard-of-care chemotherapy, a checkpoint inhibitor and a non-steroidal anti-inflammatory medication slowed the progression of cancer and reduced tumor growth in animal models.